[Skip to Content]

Upstate Active Clinical Trials

Study Title:

AFT-57: Randomized Phase II Trial of Neoadjuvant and Adjuvant Atezolizumab with or without Tiragolumab in Conjunction with Chemoradiotherapy for Unresectable Stage III NSCLC

What is the purpose of the study? (in Layman's terms, please describe the study)

The purpose of this study is to compare the safety and effects of atezolizumab with or without tiragolumab to find out what effects, good or bad, this study treatment has on you and your cancer.

Upstate Institutional Review Board (IRB) Number:

2072592

Study/Protocol ID:

AFT-57

Study Phase:

II

Patient Age Group:

Adults

Principal Investigator:

Michael D Mix, MD

Who is eligible?

You may be eligible to take part in this study if you have been diagnosed with non-small cell lung cancer (NSCLC). Other inclusion criteria apply. Please contact the CRA for more information.

What is involved if I participate?

  • How long is the study?
    2 years.
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    Please contact the CRA for more information.

Where will the study take place?

Upstate Cancer Center at Verona
Upstate Cancer Center at Oswego
Upstate University Hospital Community Campus

Other Information:

Please contact the CRA for more information.

Who can I contact for more information?

Name: Erin Bingham, CCRP
Phone: 315-464-3603
Email: [email protected]

Return to Previous Page || Search Again

Top